3 Canadian Stocks to Buy Before the Next Trade Headline Hits

Trade headlines can whipsaw the TSX, so these three stocks have catalysts and “bad news” pricing that could spark sharp moves.

Amy Legate-Wolfe

Author Bio Amy became interested in investing in 2018 after having her first daughter. After receiving a masters degree in journalism from Western University, she became frustrated that the finance industry remained a confusing place for Canadians like her: new parents, millennials, and other young people who needed to understand their finances. Now, Amy focuses on tech companies and renewable energy for growth opportunities, coupling that with long-term investing strategies and equities. She also provides investors with a daily newsletter, Canada Stock Digest, for daily market updates. Her work can also be found at Canada's National Observer, where she writes on the business side of climate action. Before joining Motley Fool Canada, Amy wrote for major news organizations including HuffPost, CTVNews.ca, and CBC. When she’s not researching investing strategies, Amy’s time is pretty much monopolized by her two wild daughters, but in what little spare time she has she loves to do yoga, go on walks with her dog, and travel with her husband. Social Media Follow Amy on LinkedIn and Canada Stock Digest. Favorite Investment Quote “October: This is one of the particularly dangerous months to speculate in stocks. The others are July, January, September, April, November, May, March, June, December, August and February.” – Mark Twain

Published May 11, 8:00 pm EDT

Trade headlines can shake the TSX in a hurry. One tariff threat, currency swing, or supply-chain scare can send investors scrambling. That’s why the best stocks to buy before the next headline are not always the smoothest names. They’re companies with clear assets, deep discounts, or domestic businesses that already have bad news priced in. In a jumpy market, investors want stocks with a reason to move when sentiment shifts, not just companies that look calm on the surface.

social media scrolling on phone networking — Source: Getty Images

ABX

Barrick Mining (TSX: ABX) produces gold and copper across a global portfolio, making it a natural hedge when trade tensions, inflation fears, or geopolitical worries flare up. Over the last year, gold prices helped lift earnings, and Barrick stock also worked to simplify its story. Its planned initial public offering of North American gold assets could unlock value by separating its stronger North American mines from riskier global operations.

The latest results were strong. For 2025, Barrick stock reported revenue of US$17 billion, operating cash flow of US$7.7 billion, and free cash flow of US$3.9 billion. Net earnings per share came (EPS) in at US$2.93, while adjusted EPS reached US$2.42. The company also lifted shareholder returns and moved toward a dividend policy tied to free cash flow. The valuation still looks reasonable for a major gold producer, with the stock recently trading around 13 times earnings. The risks are mine disruptions, political issues, and a pullback in gold. But if trade headlines get messy again, Barrick stock gives investors a sturdy hard-asset angle.

BHC

Bausch Health (TSX: BHC) is a very different kind of opportunity. The Laval-based healthcare company sells pharmaceuticals, medical aesthetics products, and owns a major stake in Bausch + Lomb. It’s not a clean, low-risk story. Debt remains the big issue, and investors still remember the company’s messy past. Yet that’s also why the stock can move sharply when results improve. Over the last year, Bausch kept growing revenue, generated more cash, and continued looking for ways to unlock value from its Bausch + Lomb stake.

Its latest numbers showed better momentum. In the fourth quarter of 2025, consolidated revenue rose 9% to US$2.8 billion. For the full year, revenue reached US$10.3 billion, up 7%. In the first quarter of 2026, Bausch Health excluding Bausch + Lomb delivered its 12th straight quarter of year-over-year revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) growth, with revenue up 14% and adjusted EBITDA up 17%. The stock recently traded around 13 times trailing earnings, while the forward valuation looked much cheaper. The risk remains debt and execution, but healthcare demand can hold up better than many cyclical areas, and any successful value-unlocking move could change the story fast.

CJR

Corus Entertainment (TSX: CJR.B) looks like the kind of beaten-down stock that could surprise if the next headline hits the right way. Corus owns Global Television, specialty channels, radio stations, kids content, and digital media assets. The business has struggled with weak advertising, lost content rights, cord-cutting, and heavy debt. Over the last year, Corus cut costs, shut some weaker channels, paused parts of its animation business, and pushed through a proposed recapitalization aimed at stabilizing the balance sheet.

The latest earnings were not pretty, but they were not hopeless either. In the second quarter of fiscal 2026, consolidated revenue fell 15% to about $230 million. Yet segment profit rose 72% to $30.2 million, helped by aggressive cost control. Corus still reported a net loss of $6.1 million, or $0.03 per share. For fiscal 2025, revenue was $1.13 billion and segment profit was $189 million, though leverage sat at a heavy 6 times net debt to segment profit. This is now a potential stock offering a deeply depressed valuation, so any improvement in advertising, regulation, debt terms, or buyer interest could matter.

Bottom line

Barrick, Bausch Health, and Corus all come with different levels of risk. Barrick stock offers safety through gold and cash flow, Bausch offers healthcare demand and turnaround potential, and Corus offers deep-value upside for brave investors. Before the next trade headline hits, I’d rather own stocks with specific catalysts than chase whatever already looks comfortable.